These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. Hempel RJ; Tulen JH; van Beveren NJ; Röder CH; Hengeveld MW J Psychopharmacol; 2009 Aug; 23(6):697-707. PubMed ID: 18562420 [TBL] [Abstract][Full Text] [Related]
4. Evaluating subjective domains of antipsychotic-induced adverse effects using heart rate variability. Chang JS; Hwang SS; Yi SH; Kim Y; Lee YS; Kim YS; Jung HY Psychiatry Clin Neurosci; 2015 May; 69(5):283-91. PubMed ID: 25066617 [TBL] [Abstract][Full Text] [Related]
5. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317 [TBL] [Abstract][Full Text] [Related]
6. Effects of clozapine on heart rate dynamics and their relationship with therapeutic response in treatment-resistant schizophrenia. Kim JH; Yi SH; Lee J; Kim YS J Clin Psychopharmacol; 2013 Feb; 33(1):69-73. PubMed ID: 23277266 [TBL] [Abstract][Full Text] [Related]
7. [Heart rate variability in schizophrenic patients treated with antipsychotic agents]. Cohen H; Loewenthal U; Matar M; Kotler M Harefuah; 2001 Dec; 140(12):1142-7, 1231. PubMed ID: 11789296 [TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine on the PR and QT intervals in patients with schizophrenia. Suzuki Y; Ono S; Tsuneyama N; Sawamura K; Sugai T; Fukui N; Watanabe J; Someya T Schizophr Res; 2014 Jan; 152(1):313-4. PubMed ID: 24275577 [No Abstract] [Full Text] [Related]
9. Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up. Wang YC; Yang CC; Bai YM; Kuo TB Neuropsychobiology; 2008; 57(4):200-5. PubMed ID: 18679039 [TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981 [TBL] [Abstract][Full Text] [Related]
11. Non-linear complexity measures of heart rate variability in acute schizophrenia. Bär KJ; Boettger MK; Koschke M; Schulz S; Chokka P; Yeragani VK; Voss A Clin Neurophysiol; 2007 Sep; 118(9):2009-15. PubMed ID: 17646130 [TBL] [Abstract][Full Text] [Related]
12. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
13. Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis. Wang J; Liu YS; Zhu WX; Zhang FQ; Zhou ZH Sci Rep; 2014 Dec; 4():7394. PubMed ID: 25487560 [TBL] [Abstract][Full Text] [Related]
14. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384 [TBL] [Abstract][Full Text] [Related]
15. Nonlinear complexity and spectral analyses of heart rate variability in medicated and unmedicated patients with schizophrenia. Mujica-Parodi LR; Yeragani V; Malaspina D Neuropsychobiology; 2005; 51(1):10-5. PubMed ID: 15627808 [TBL] [Abstract][Full Text] [Related]
16. Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. Mann K; Rossbach W; Müller MJ; Müller-Siecheneder F; Ru H; Dittmann RW Int Clin Psychopharmacol; 2004 Nov; 19(6):325-30. PubMed ID: 15486517 [TBL] [Abstract][Full Text] [Related]